Fenretinide

Generic Name: Fenretinide

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₃NO_₂

CAS Number: 65646-68-6

Unique Ingredient Identifier: 187EJ7QEXL

Background: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Indication: Investigated for use/treatment in macular degeneration.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Stage IV Ovarian Epithelial Cancer
Stage IV Primary Peritoneal Cavity Cancer

Interventions: Drug: fenretinide
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00026091

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Fenretinide

First Posted Date: 2003-01-27

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00006471

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: fenretinide

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00009971

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT00005819

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Phase 3

Completed

Conditions: Bladder Cancer

Interventions: Other: Placebo
Drug: Fenretinide

First Posted Date: 2003-01-27

Last Posted Date: 2018-11-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 111

Registration Number: NCT00004154

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Veterans Affairs Medical Center - Seattle, Seattle, Washington, United States

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer
Breast Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00001378

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy